http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2011124527-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-545 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2887 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-50 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-30 |
| filingDate | 2009-11-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2012-12-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2011124527-A |
| titleOfInvention | METHOD AND COMPOSITION FOR REDUCING MACROMOLECULE AGGREGATION IN PHYSIOLOGICAL CONDITIONS |
| abstract | 1. A method of minimizing inflammation at the injection site during subcutaneous administration of a macromolecule, comprising adding to the composition containing the macromolecule, from 5% to 20% polyvinylpyrrolidone (PVP) having a molecular weight in the range from 2000 to 54000 daltons. 2. The method of claim 1, wherein the macromolecule is a protein. The method of claim 2, wherein the protein is an antibody. The method of claim 3, wherein the antibody is a therapeutic antibody. The method of claim 3, wherein the antibody is a diagnostic antibody. The method of claim 3, wherein the antibody is an anti-CD20 antibody. The method according to claim 6, where the antibody contains an antibody variant A, B, C, D, F, G, H or I, as shown in Table 1.8. The method according to claim 6, where the antibody contains an amino acid sequence selected from the group consisting of SEQ ID NO: 1-15.9. The method of claim 6, wherein the antibody comprises a light chain variable domain of SEQ ID NO: 1 and a heavy chain variable domain of SEQ ID NO: 2.10. The method according to claim 6, where the antibody contains the variable domain of the light chain of SEQ ID NO: 3 and the variable domain of the heavy chain of SEQ ID NO: 4.11 The method according to claim 6, where the antibody contains the variable domain of the light chain of SEQ ID NO: 3 and the variable domain of heavy chains of SEQ ID NO: 5.12. The method of claim 6, wherein the antibody comprises a full-length light chain of SEQ ID NO: 6 and a full-length heavy chain of SEQ ID NO: 7.13. The method of claim 6, wherein the antibody comprises a full-length light chain of SEQ ID NO: 6 and a full-length heavy chain of SEQ ID NO: 15.14. The method of claim 6, wherein the antibody comprises a full-length light chain of SEQ ID NO: 9 and a full-length heavy chain of SEQ ID NO: 10.15. The method of claim 6, wherein the antibody comprises a full-length light chain of SEQ ID NO: 9 and a full-length heavy chain of SEQ ID NO: 11.16. The method of claim 6, wherein the antibody comprises a full-length light chain of SEQ ID NO: 9 and a heavy chain� |
| priorityDate | 2008-11-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 41.